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Abstract: Hypoxia and endothelial dysfunction play a central role in the development of 
pulmonary hypertension. Cor pulmonale is a maladaptive response to pulmonary hyperten-
sion. The presence of peripheral edema in cor pulmonale is almost invariably associated with 
hypercapnia. Correction of abnormalities of gas exchange and ventilation can ameliorate 
pulmonary hypertension and improve survival. This review focuses on new information about 
the pathogenesis and treatment of pulmonary hypertension in COPD including information 
derived from lung volume reduction surgery, the role of brain natriuretic peptide, exhaled 
nitric oxide for diagnosis, and the treatment of cor pulmonale with recently available speciﬁ  c 
pulmonary vasodilators.
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Introduction
Cor pulmonale was classically deﬁ  ned as “hypertrophy of the right ventricle resulting 
from diseases affecting the function and/or structure of the lungs except when these 
pulmonary alterations are the result of diseases that primarily affect the left side of the 
heart” (WHO expert committee report 1963). Since this deﬁ  nition does not indicate 
the presence of right heart failure, and since the presence of edema does not always 
imply underlying right heart failure in stable COPD patients, the terms cor pulmonale 
and right heart failure are not synonymous. Pulmonary hypertension (PH) however 
is always the underlying pathologic mechanism for right venrticular hypertrophy in 
cor pulmonale.
Pulmonary hypertension in COPD is placed in group 3 of the 2003 WHO classiﬁ  -
cation of PH (Rubin 2004), ie, PH associated with disorders of the respiratory system 
and/or hypoxemia. PH associated with lung disease is deﬁ  ned as resting mean PAP 
(mPAP) greater than 20 mm Hg (Weitzenblum 2003), which is different from the 
deﬁ  nition of primary pulmonary hypertension (mPAP 25 mm Hg).
Prevalence
The exact prevalence of PH and cor pulmonale in COPD is unknown because it is not 
feasible to perform right heart catheterization on a large scale. The reported prevalence 
varies considerably from 20%–91% (Burrows et al 1972; Weitzenblum et al 1984; 
Oswald-Mammosser et al 1991; Scharf et al 2002; Thabut et al 2005) depending on the 
deﬁ  nition of pulmonary hypertension, the severity of lung disease in the group studied 
and the method of measuring the PAP. In a large series of patients with advanced COPD 
referred for lung volume reduction surgery the prevalence of pulmonary hypertension 
is reported as just over 50% (Thabut et al 2005).
In severe COPD patients with or without resting PH, steady-state exercise may 
raise PAP to about twice the level of its resting value because PVR fails to decrease International Journal of COPD 2007:2(3) 274
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(Weitzenblum 2003). In severe COPD activities of daily living 
such as climbing stairs or walking can induce transient PH.
During an exacerbation of COPD, PAP may rise by as 
much as 20 mm Hg and return to its baseline after recovery 
(Abraham et al 1969; Weitzenblum et al 1979). In patients 
with advanced COPD, oxygen saturation may fall during 
REM sleep by 20%–30% (Catterall et al 1983; Fletcher 
et al 1984) and PAP may rise by as much as 20 mm Hg 
(Coccagna and Lugaresi 1978). It remains unproven that 
nocturnal desaturation in COPD leads to the development 
of pulmonary hypertension and cor pulmonale (Fletcher 
et al 1992; Chaouat et al 2001).
Pathophysiology of pulmonary 
hypertension and cor pulmonale 
in COPD
Traditionally, PH in COPD has been considered to be the 
result of hypoxic pulmonary vasoconstriction, polycythemia 
and destruction of the pulmonary vascular bed by emphy-
sema. Recently, it has been recognized that hyperinﬂ  ation 
and endothelial dysfunction also play a role in the patho-
genesis of PH.
Hypoxic pulmonary vasoconstriction (HPV) is an 
adaptive response to divert blood away from the poorly 
ventilated alveoli to maintain ventilation-perfusion balance 
and a normal PaO2. Classic studies show that a decreased 
hydrogen ion concentration augments hypoxic pulmonary 
vasoconstriction (Enson 1964).
Acute hypoxia inhibits specific voltage-gated potassi-
um (Kv) channels and induces influx of cytosolic calcium, 
which triggers membrane depolarization in pulmonary 
artery smooth muscle cells (PASMCs) and leads to pul-
monary vasoconstriction (Weir EK et al 2005). Chronic 
hypoxia selectively inhibits messenger RNA and protein 
expression of the Kv channel pore forming α-subunits 
and decreases the number of functional Kv channels in 
PASMCs. The consequent reduction in potassium cur-
rents through the Kv channels depolarizes PASMCs, 
raises cytosolic calcium, stimulates cell proliferation 
(Sweeney and Yuan 2000) and inhibits apoptosis. The 
resultant vascular remodeling is characterized by intimal 
fibrosis and proliferation of longitudinal smooth muscle, 
neomuscularization of pulmonary arterioles and medial 
hypertrophy of small pulmonary arteries (Wilkinson et al 
1988) ( Figure 1). After remodeling occurs, the narrower, 
thicker and more muscular pulmonary arteries are less 
compliant and offer higher resistance to flow.
Destruction of the pulmonary vascular bed in emphysema 
reduces the total cross-sectional area of the pulmonary circu-
lation and increases the total pulmonary vascular resistance 
when the remaining capacitance vessels are abnormal and 
unable to accommodate the increased diverted pulmonary 
blood ﬂ  ow.
The inverse relationship between FEV1 and pulmonary 
hypertension has been reported (Oswald-Mammoser et al 
1991) yet pulmonary hypertension can develop in those 
without signiﬁ  cant resting hypoxemia. Severe emphysema 
with air-trapping and hyperinflation is associated with 
intrinsic positive end-expiratory pressure of 5–7.5 cm H2O 
(Tschernko et al 1998). The positive alveolar pressure 
throughout respiration contributes to the high pulmonary 
vascular resistance and PH. This mechanism may assume a 
more important role in development of PH in patients with 
severe emphysema who are not hypoxemic and also perhaps 
during exercise in some patients. In a hemodynamic study 
of 120 non-hypoxemic patients evaluated for lung volume 
reduction surgery (Scharf et al 2002), a mPAP 20 mm Hg 
occurred in 90.8%. In this study however wedge pressure was 
greater than 12 mmHg in over 60%. It is unclear whether 
the reduction in hyperinﬂ  ation following LVRS signiﬁ  cantly 
ameliorates PH independently of improved arterial oxygen 
tension.
Pulmonary vascular endothelial dysfunction is a major 
factor in the pathogenesis of pulmonary hypertension. The 
balance between constriction and dilatation is maintained 
by a number of small molecular mediators one of the more 
important of which is nitric oxide (NO). Nitric oxide (NO) 
has vasodilator and anti-proliferative properties is produced 
by endothelial NO synthase (eNOS). Prostacyclin, another 
vasodilator that also protects against vascular remodeling, is 
produced by the activity of prostacyclin synthase. Countering 
vasodilation is endothelium-derived endothelin-1 (ET-1).
An imbalance of vasoconstriction opposed to dilatation 
is likely to be involved in the pathogenesis of pulmonary 
hypertension in COPD. In patients with COPD and PH 
there is a reduction in the synthesis and/or release of NO 
from the lung (Dinh-Xuan et al 1991; Clini et al 2000; Clini 
et al 2002). In COPD there is a reduction in the expression 
of prostacyclin synthase mRNA (Lee et al 2005), and an 
excessive expression of endothelin-1 (ET-1) (Giaid et al 
1993) in the pulmonary arteries of patients with secondary 
pulmonary hypertension. Arterial ET1 increases shortly after 
episodes of nocturnal oxygen desaturation in patients with 
COPD and remains higher during the day in these subjects 
(Spiropoulos et al 2003).International Journal of COPD 2007:2(3) 275
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The pulmonary vascular response to hypoxia is geneti-
cally determined. Serotonin (5-hydroxytryptamine, 5-HT) 
and its transporter (5-HTT) play a role in PASMC prolifera-
tion and vascular remodeling. In animal studies hypoxia is a 
strong inducer of 5-hydroxytryptamine transporter (5-HTT) 
expression, which leads to a greater mitogenic response of 
PASMC to 5HT (Eddahibi et al 1999). The severity of PH 
in hypoxic COPD patients depends upon 5-HTT gene poly-
morphism. PH is most severe in patients carrying the LL 
genotype, which is associated with higher levels of 5-HTT 
expression in PASMCs (Eddahibi et al 2003).
Angiotensin converting enzyme (ACE) in the lung 
converts Angiotensin 1 to A2, a vasoconstrictor and mediator 
of PASMC proliferation. ACE is present in very high con-
centrations in the lungs and its activity is further increased 
by hypoxia (King et al 1989). The ACE gene contains 
a polymorphism based on the presence (insertion [I]) or 
absence (deletion [D]) of a nonsense DNA domain, result-
ing in three genotypes (DD, DI or II) (Rigat et al 1992). The 
ACE DD genotype is associated with increased circulating 
and tissue concentrations of ACE. Moreover, the ACE DD 
genotype is associated with exaggerated PH during exercise 
in COPD patients (Kanazawa et al 2000). Future studies could 
be designed to enroll populations with COPD genetically 
susceptible to PH for new therapeutic trials.
Right and left ventricular function in cor 
pulmonale
Classic hemodynamic studies have shown the existence 
of two patterns of cardiovascular abnormalities in COPD 
patients with high pulmonary vascular resistance. Patients 
with predominant “emphysema” have mild hypoxia, mild 
pulmonary hypertension at rest, and low cardiac index with 
dyspnea (“the pink puffer”). On the other hand, patients with 
predominant “chronic bronchitis” have more severe hypoxia 
in association with hypercapnia, more severe pulmonary 
hypertension peripheral edema and a normal cardiac index 
(“the blue bloater”) (Khaja and Parker 1971; Burrows et al 
1972). These distinctions have become less useful conceptu-
ally as it is increasingly recognized that many patients show 
features of both types. In addition later work has indicated 
that the classic deﬁ  nition may not hold. For example, cardiac 
output in the “pink puffer type” has been found to be normal 
(Oswald Mammoser et al 1991).
In response to the increased pulmonary vascular resis-















Figure 1 Pathophysiology of cor pulmonale in COPD.  
Abbreviations: NO, nitric oxide; ET-1, endothelin-1; PVR, pulmonary vascular resistance; PH, pulmonary hypertension.International Journal of COPD 2007:2(3) 276
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dilatation (cor pulmonale). This increase in end-diastolic 
volume ie, pre-load, to maintain a normal stroke volume 
accounts for the reduced right ventricular ejection fraction. 
The right ventricular stroke work index probably remains 
normal even during exercise and explained by greater pres-
sure work and the expense of RV output (Khaja and Parker 
1971). However, in severe emphysema hyperinﬂ  ation, the 
low elastic recoil of the lungs and less negative intrathoracic 
pressure has the effect of compressing the two ventricles into 
each other (Sciurba et al 1996). The RV is therefore unable 
to dilate and end-diastolic volume does not increase. This 
decreases RV preload and results in lower cardiac output. 
A decrease in intrathoracic pressure as may occur after lung 
volume reduction surgery, redistributes the blood volume to 
the thoracic compartment and increases RV and LV preload 
and cardiac function (Jorgenen et al 2003).
Changes in RV output must invariably alter LV preload, 
because the two ventricles are serially linked through the pul-
monary vasculature. LV preload can also be directly altered 
by changes in RVEDV by the mechanism of ventricular 
interdependence. The increased RVEDV in cor pulmonale 
induces a shift of the interventricular septum into the LV and 
decreases LV diastolic compliance but this does not adversely 
affect LV output because the increased RV systolic pressure 
in cor pulmonale also pushes the septum into the LV towards 
its free wall to empty the LV. This “help” from the RV in 
systole tends to preserve LV ejection fraction (LVEF) in 
emphysematous patients with severe RV hypertrophy (Dong 
et al 1995; Vonk Noordegraaf et al 1997).
RV contractility, as assessed by end systolic pressure-
volume relation, is normal in stable COPD patients and the 
RV operates on an extension of the normal RV function 
Frank-Starling curve. During an exacerbation, the RV end-
diastolic pressure and volume rise and RV ejection fraction 
falls, resulting in peripheral edema and systemic congestion 
(MacNee et al 1988; Weitzenblum et al 1994). These changes 
may not be associated with a rise in PAP suggesting other 
factors reduce RV contractility (MacNee et al 1988).
Diagnosis of cor pulmonale 
in COPD
Clinical features
The clinical exam lacks sensitivity and specificity. 
Hyperinﬂ  ation reduces the yield of cardiac auscultation for 
the classic signs of PH and CP ie, loud P2, S3 gallop, the 
systolic murmur of tricuspid regurgitation. Peripheral edema 
can be present in the absence of right heart failure in COPD 
(Weitzenblum et al 1994) and is not diagnostic of cor pul-
monale. The pathogenesis of edema formation in COPD is 
complex. Renal blood ﬂ  ow is reduced, the renin-angiotensin 
system is activated, renal dopamine output is reduced and 
plasma ANP level is elevated leading to increase in proximal 
renal tubular sodium reabsorption (Skwarski et al 1998; de 
Leeuw and Dees 2003). Sodium retention is enhanced by 
hypercapnia and ameliorated by long-term oxygen therapy 
in hypoxemic patients (Bratel et al 2003). True right heart 
failure is characterized by raised jugular venous pressures, 
congestive hepatomegaly as well as peripheral edema.
Pulmonary function tests
The Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines does not recommend the routine 
measurement of the PAP in patients with COPD (workshop 
report 2005). Early studies indicate that, with the exception 
of low oxygen tensions during exercise and resting hyper-
capnia, pulmonary function tests are poor predictors of the 
severity of pulmonary hypertension in COPD (Keller et al 
1986). However in a selected group of patients undergoing 
LVRS the level of PAP varies inversely with the FEV1 
(Scharf et al 2002; Thabut et al 2005). Similarly studies 
of COPD patients without severe hypoxia (PaO2  55 mm 
Hg) have also shown that mPAP better correlates with the 
FEV1 than with the resting PaO2 (Oswald-Mammosser et al 
1991; Doi et al 2003). It is also notable that these studies 
indicating a closer FEV1 PAP relationship were conducted 
in patients with severe hyperinﬂ  ation which itself is likely 
to predispose to PH.
Chest radiography
An increase in the diameter of the right descending pulmonary 
artery to more than 16 mm on the postero-anterior projection 
combined with a diameter of the left descending pulmonary 
artery of more than 18 mm on the left lateral projection can 
identify PH with 98% sensitivity (Matthay et al 1981).
EKG
The sensitivity for right ventricular hypertrophy is only 
25%–40%. Presence of S1S2S3 or right atrial overload pattern 
ie, P wave axis of +90° or more, implies a poor prognosis 
(Incalzi et al 1999).
Echocardiography
Hyperinﬂ  ation precludes optimal visualization of the heart. 
In a cohort of lung transplant candidates estimation of 
systolic PAP (sPAP) was possible in only 38% of the 253 International Journal of COPD 2007:2(3) 277
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patients with COPD. Hyperinﬂ  ation with a residual volume 
of greater than 150% lessened the likelihood of sPAP esti-
mation. Sensitivity, speciﬁ  city, negative predictive value 
and positive predictive value of sPAP estimated by echocar-
diography for the diagnosis of PH were 76, 65, 93, and 32 
per cent, respectively (Arcasoy et al 2003). In the absence 
of sPAP estimation, ﬁ  gures for right ventricular abnormali-
ties were 84, 56, 96, and 22 per cent respectively. Although 
the negative predictive value is high enough to exclude PH, 
the presence of a high sPAP or RV abnormalities requires 
conﬁ  rmation by right heart catheterization.
Magnetic resonance imaging
In COPD, the echocardiographic window might be obscured 
by hyperinﬂ  ation. Contrast MRI provides excellent images 
of right ventricular structure and function. Right ventricular 
wall thickness has a high correlation with the mean PAP 
(r = 0.9) (Saito et al 1992). Readers are referred to McGoon 
et al (2004) for further details.
Right heart catheterization
Right heart catheterization is the gold standard to determine 
the exact PAPs. It also allows measurement of the trans-
pulmonary gradient, measurement of cardiac output, with 
calculation of the pulmonary vascular resistance and deter-
mination of reversibility with a vasodilator. Exercise induced 
pulmonary hypertension can also be evaluated.
The degree of PH in stable COPD is usually mild to 
moderate (mPAP 35 mm Hg). A mPAP 40 mm Hg is 
rare in COPD and should initiate a search for an additional 
cause of PH eg, left heart disease, sleep apnea syndrome, pul-
monary embolism. Rarely a COPD patient may present with 
severe PH (Chaouat et al 2005; Thabut et al 2005). They are 
characterized by mild to moderate airway obstruction, severe 
hypoxemia, hypocapnia and a very low diffusing capacity 
(Table 1). They also suffer from more severe exertional 
dyspnea and have a shorter survival (Chaouat et al 2005). 
These patients may have an exaggerated response to chronic 
hypoxemia as may be seen in certain high altitude dwellers 
(Maggiorini et al 2003).
Brain natriuretic peptide
Plasma plasma brain natriuretic peptide (BNP) may provide 
a reliable and accurate diagnostic test for PH. BNP is a 
cardiac hormone, which is synthesized by the ventricle and 
secreted into the circulation in response to increased wall 
stretch and tension during elevations in end-diastolic pressure 
(Yamamoto et al 1996). BNP seems promising as a marker for 
pulmonary hypertension and right ventricular dysfunction. 
One study of 38 patients with stable COPD, 20 of whom had 
clinical cor pulmonale, found signiﬁ  cant correlation between 
BNP and echocardiographically determined PASP (r = 0.68, 
p  0.001) (Bozkanat et al 2005). Increased BNP also corre-
lated with lower arterial oxygen tensions suggesting that BNP 
can also be released in response to hypoxia. More recently, 
BNP has been reported to provide prognostic information in 
patients with chronic lung disease (Leuchte et al 2006). Given 
the limitations of these small studies larger scale studies are 
required to determine if BNP offers speciﬁ  c diagnostic and 
prognostic information especially in the presence of left heart 
disease and/or chronic hypoxemia.
Exhaled nitric oxide
Clini et al measured levels of exhaled nitric oxide (eNO) in 
COPD patients including those with cor pulmonale. First they 
studied 34 consecutive patients with stable COPD and found 
that using a sPAP of 35 mm Hg as cut-off, patients with cor 
pulmonale showed lower values of eNO compared to those 
with normal resting sPAP (Clini et al 2000). The study was 
limited by the use of echocardiography to measure PAP but 
reduced exhaled NO in COPD patients with cor pulmonale 
compare to those without is a plausible ﬁ  nding.
Two years later the same group published the results of 
changes in eNO in a prospective, controlled study of 47 stable 
COPD patients who underwent a multi-disciplinary pulmo-
nary rehabilitation program for 8–10 weeks. They found that 
both peak workload and eNO increased signiﬁ  cantly and 
independent of the severity of airway obstruction, in all the 
patients except the 7 with cor pulmonale on LTOT (Clini 
et al 2002). The authors did not indicate whether the group 
with cor pulmonale received oxygen during rehabilitation.
At this time the role of the test to diagnose PH in COPD and 
monitor the response to therapy remains uncertain.
Therapy of cor pulmonale
Although pulmonary hypertension in COPD is usually mild 
(mPAP 20–35 mm Hg), it may increase markedly during 
exercise (Horsﬁ  eld et al 1968; Weitzenblum 2003), sleep 
(Coccagna et al 1978; Catterall et al 1983; Fletcher et al 
1984), and exacerbations (Weitzenblum et al 1994). Frequent 
exacerbations can promote the development of right heart 
failure and this should be preventable by general management 
measures recommended for COPD.
Oxygen is the best pulmonary vasodilator in COPD 
patients with cor pulmonale but not all patients beneﬁ  t 
from it. Calcium channel blockers, β2-agonists, nitrates, International Journal of COPD 2007:2(3) 278
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angiotensin converting enzyme inhibitors, theophylline, and 
α1-antagonists have also been used. (MacNee 2004). Most 
of these cause a modest fall in PH accompanied by a rise in 
cardiac output and a reduced pulmonary vascular resistance. 
Most of them are also associated with systemic hypotension 
and with worsening of ventilation-perfusion mismatch that 
may or may not be offset by the improvement in cardiac 
output. None has been studied long enough to determine any 
survival beneﬁ  t (MacNee 2004).
Oxygen
Although acute oxygen therapy may not improve hemody-
namics signiﬁ  cantly (MacNee et al 1988), two landmark trials 
conducted more than twenty years ago by the US National 
Institute of Health and the UK Medical Research Council 
showed that continuous long-term oxygen therapy (LTOT) 
improves survival and prevents progression of PH (noctur-
nal oxygen therapy trial group 1980; MRC working party 
1981). Follow up of hypoxemic COPD patients on LTOT 
for 6 years demonstrated a reversal but not normalization 
of PH (Weitzenblum et al 1985). Another long term study 
conﬁ  rmed this ﬁ  nding (Zielinski et al 1998). Reduced patient 
compliance with oxygen therapy may be an issue limiting 
the effectiveness of this treatment.
Unfortunately not all the patients with COPD who meet 
criteria for LTOT beneﬁ  t from it. Patients who exhibit a 
signiﬁ  cant drop in mean PAP of more than 5 mm Hg after 
acute oxygen therapy (28% for 24 hours) have an 88% 2 year 
survival compared to 22% in non-responders when both groups 
of patients are subsequently treated with continuous LTOT 
(Ashutosh et al 1983). Similarly in the nocturnal oxygen ther-
apy trial continuous LTOT resulted in an improved survival 
only in patients whose baseline pulmonary vascular resistance 
was not greater than 400 dyne.s.cm–5 (Timms et al 1985). 
Pulmonary vascular remodeling may limit the effectiveness 
of oxygen induced vasodilation in some patients. Oxygen 
therapy during exercise and sleep ameliorates the rise in mean 
PAP (Horsﬁ  eld et al 1968; Keisaku et al 2002; Raeside et al 
2002) in moderate to severe COPD. Whether such therapy 
prevents the eventual development of pulmonary hypertension 
in susceptible subjects is unknown.
Pulmonary vasodilators
The limitations of LTOT in improving PAP provide an 
impetus for the development of additional therapies.
Inhaled nitric oxide
Inhaled nitric oxide (iNO) is a more potent vasodilator than 
oxygen. However, when used alone iNO worsens ventilation-
perfusion imbalance. In a randomized controlled trial of 40 
patients with severe COPD receiving LTOT, pulsed iNO was 
delivered with oxygen for 3 months (Vonbank et al 2003). 
There was a signiﬁ  cant improvement in mPAP, pulmonary 
vascular resistance, and cardiac output (Table 2). Systemic 
hemodynamics and left heart function remained unchanged. 
PaCO2 decreased signiﬁ  cantly in the treatment group, sug-
gesting improved perfusion of the better ventilated areas. 
Although the delivery of nitric oxide as a practical approach 
to treatment still has signiﬁ  cant obstacles, particularly cost, 
this study shows a promising role for selective pulmonary 
vasodilators in COPD.
Sildenaﬁ  l
The phosphodiesterase 5 inhibitor sildenaﬁ  l is a speciﬁ  c 
pulmonary vasodilator and increases the effects of iNO 
through the cGMP pathway. It relaxes human PASMCs by 
Table 1 Comparison of COPD patients without other causes of pulmonary hypertension
  Severe PH group (without  Control group with less  p value
  additional causes of PH &  severe PH (mPAP ≥ 20
 mPAP  ≥40 mm Hg) (N = 11)  mm Hg) (N = 16)
FEV1 (% predicted)  50 (44–56)  27 (23–34)  <0.01
DLCO (ml/min/mm Hg)  4.6 (4.2–6.7)  10.3 (8.9–12.8)  <0.01
PaO2 (mm Hg)  46 (41–53)  56 (54–64)  <0.01
PaCO2 (mm Hg)  32 (28–37)  47 (44–49)  <0.01
RAP (mm Hg)  7 (5–9)  3 (1.3–4)  <0.01
mPAP (mm Hg)  48 (46–50)  25 (22–27)  <0.01
PCWP (mm Hg)  6 (4–7)  7 (6.5–7.5)  NS
CI (L/min/m2)  2.3 (1.8–2.5)  2.8 (2.4–3.1)  <0.01
TPR (IU/m2) 21.3  (17.6–26.6)  9  (7.4–9.9)  <0.01
Adapted with permission from Chaouat A, Bugnet A, Kadaoui N, et al. 2005. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care 
Med, 172:189–94. Ofﬁ  cial Journal of the American Thoracic Society. © American Thoracic Society.
Abbreviations: FEV1, forced expiratory volume in the ﬁ  rst second; DLCO, diffusing capacity; RAP, right atrial pressure; mPAP, mean pulmonary artery pressure; PCWP, 
pulmonary capillary wedge pressure; CI, cardiac index; TPR, total pulmonary resistance; IU, international units.International Journal of COPD 2007:2(3) 279
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Table 2 Comparison of patients treated with oxygen alone versus oxygen and inhaled nitric oxide
    Oxygen alone      Oxygen + iNO 
  Baseline  After Baseline  After p  value
    3 months    3 months
mPAP (mm Hg)  24 ± 5  25 ± 6  27 ± 4  20 ± 5  <0.001
PVR (dyn × s/cm5)  259 ± 101  264 ± 109  276 ± 96  173 ± 87  0.001
CO (l/min)  5.5 ± 1.3  5.3 ± 1.3  5.6 ± 1.3  6.1 ± 1.0  0.025
VO2 (ml/min)  883 ± 303  842 ± 232  896 ± 406  1005 ± 326  NS
Adapted from Chaouat et al (2001).
Abbreviations: mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; CO, cardiac output;  VO2, oxygen consumption.
inhibiting PDE 5 thereby activating large conductance cal-
cium activated potassium channels (Michelakis et al 2003). 
It has been used successfully in primary PH (Michelakis 
et al 2003), scleroderma (Ghofrani et al 2002), and chronic 
thromboembolic disease (Ghofrani et al 2003). However, it 
has been studied in COPD patients in only one small open 
label trial of sildenaﬁ  l 50 mg orally twice daily for 3 months 
(Alp et al 2005). The mPAP and PVR decreased signiﬁ  cantly 
and the 6 minute walk distance (6 MWD) improved from 
351 ± 49 to 433 ± 52 m (p  0.05). This 82 m increase in 
6 MWD is greater than that seen in patients with idiopathic 
PH treated with other pulmonary vasodilators bosentan and 
iloprost (Alp et al 2005). However without further studies in 
COPD, the effectiveness of sildenaﬁ  l is speculative.
Reduction in hematocrit
Polycythemia increases the viscosity of blood, the resis-
tance to blood ﬂ  ow through the pulmonary circulation and 
augments hypoxic pulmonary vasoconstriction by causing 
a local deﬁ  ciency of nitric oxide (NO) (Deem et al 1998; 
Azarov et al 2005). Phlebotomy is indicated in patients with 
a severe elevation in hematocrit not responding to LTOT, 
yet its effects may be short lived. After repeated phlebotomy 
followed by volume replacement over 3 months, Borst et al 
(1999) showed improvement in exercise tolerance with a 
fall in mean PAP. The mean Hct in this group of 7 was 
53, lower than is commonly associated with the need for 
phlebotomy.
Activation of the renin-angiotensin system may contrib-
ute to polycythemia in COPD (Vlahakos et al 1999). Plasma 
renin and aldosterone levels are increased in such patients 
when matched with controls for hypoxemia. The mechanism 
of action is serum erythropoietin independent. In a small 
study, losartan was used in weekly escalating doses to a 
maximum of 100 mg daily for 4 weeks in 9 stable severe 
COPD patients with polycythemia (hematocrit 52%). The 
regimen caused a signiﬁ  cant reduction in the hematocrit of all 
patients from 56 ± 0.9% to 46 ± 0.7% (p  0.001). The higher 
the baseline value, the greater the reduction in hematocrit 
(r = 0.7085; p  0.05) (Vlahakos et al 2001). At 3 months 
after discontinuation of losartan the hematocrit increased 
to 50 ± 0.7%. This ‘bloodless phlebotomy’ appears to be a 
promising therapy. In a randomized controlled study in 60 
COPD patients irbesartan induced a signiﬁ  cant reduction in 
hematocrit (Andreas et al 2006).
Diuretics
Diuretics reduce right ventricular dilatation and improve 
its contractility and also reduce extravascular lung water 
(Turino et al 1970). They should be used cautiously as they 
can cause intravascular volume depletion that may deprive 
the right ventricle of adequate pre-load to maintain a normal 
stroke volume. Moreover, accumulation of bicarbonate from 
diuretic therapy can worsen alveolar hypoventilation and hy-
percapnia. The latter can result ﬂ  uid retention despite diuretic 
therapy. Treatment of chronic hypercapnia may therefore be 
as important as diuretics in ameliorating sodium retention.
Lung volume reduction surgery (LVRS)
LVRS provides a model to study the effects of reduction in 
hyperinﬂ  ation and improved gas exchange on pulmonary 
hypertension. In a small study of in 9 patients who underwent 
LVRS resting mPAP remained unchanged whereas exercis-
ing mPAP decreased slightly but not signiﬁ  cantly. However, 
the improvement in arterial oxygenation during exercise was 
closely correlated with the improvement in exercise mPAP, 
whereas it was unrelated to changes in FEV1 (Oswald-
Mammoser et al 1998). It is possible that LVRS results in 
better distribution of pulmonary blood ﬂ  ow and ventilation-
perfusion matching. In another small study (Weg et al 1999) 
however mean PAP in 9 subjects rose from 26.5 to 31.8 mm 
Hg without change in pulmonary artery occlusion pressure 
3 months after surgery. In 3 patients pulmonary artery systolic 
pressure rose to 60 mm Hg or greater. In retrospect of these International Journal of COPD 2007:2(3) 280
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subjects may have been unsuitable candidates for LVRS by 
current selection criteria.
Prognosis
In the era before the widespread availability of LTOT the 
presence of PH doubled the mortality in COPD (Oswald-
Mammosser et al 1995). Studies showed an increase in PAP 
between 1.5–2.8 mm Hg/year (MRC trial 1981; Weitzenblum 
et al 1985). However, even on LTOT the 5-year survival 
rate is only 36% in those whose initial mPAP is 25 mm 
Hg compared to 66% in those whose initial mPAP is 25 
mm Hg (Oswald-Mammosser et al 1995). LTOT appears 
to stabilize but not reduce PAP indicating that other factors 
responsible for prognosis in these patients (Zielinski et al 
1998) Those who develop severe PH (mPAP 40 mm Hg) 
suffer an extremely poor prognosis (5-year survival ~15% 
vs~55% in those with less severe PH (mPAP 20–40) (Cha-
ouat et al 2005).
In those with mild or moderate hypoxemia (65 mm Hg), 
PH develops in 25% over a 6-year follow up but is usually 
mild (Kessler et al 2001). These patients are characterized 
by worsening hypoxemia and hypercapnia Those with PH 
during exercise at initial catheterization have a greater risk 
of progression (Kessler et al 2001; Weitzenblum et al 1984). 
It may be necessary to follow such patients with periodic 
arterial blood gases and BNP.
Only continuous LTOT has been shown to improve 
survival in cor pulmonale. It is unclear if this is the result of 
improved oxygen delivery to vital organs, reduction of sys-
temic inﬂ  ammation associated with COPD or of the reversal 
or stabilization of PH.
Conclusion
New insights into the central role of endothelial dysfunction 
and the availability of speciﬁ  c pulmonary vasodilators should 
renew enthusiasm in the study and treatment of PH in COPD. 
Together these have the potential to further improve survival 
in patients with COPD who develop cor pulmonale.
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